2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
January 22, 2020
Article
Ruth O’Regan, MD, and Adam M. Brufsky, MD, PhD, FACP, both discuss the emergence of trastuzumab biosimilars in breast cancer.
December 19, 2019
Video
Ruth O’Regan, MD, discusses patient education as biosimilars are implemented into practice for breast cancer.
October 02, 2019
Podcast
We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Breast Cancer, which featured insights from key thought leaders at Carbone Cancer Center of the University of Wisconsin.
September 25, 2019
Article
Conflicting guidelines on prostate-specific antigen testing have affected trends on disease presentation and, potentially, the treatment outcomes for many men with this disease. New agents and powerful new imaging tools have added yet more complexity to the decision process. Therefore, more investigation and cooperation on multiple levels is needed to define appropriate standards of care.
July 08, 2019
Article
Kari B. Wisinski, MD, highlights modern day approaches for treating patients with metastatic triple-negative breast cancer.
March 15, 2019
Article
Although the therapeutic utility of lymphadenectomy is uncertain, it continues to provide information for staging and helps to guide postoperative adjuvant treatment for patients with endometrial cancer.
December 11, 2018
Video
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the role of chemotherapy as treatment continues to advance in breast cancer.
November 27, 2018
Article
Ruth O’Regan, MD, discusses the current landscape of hormone receptor–positive breast cancer and the unanswered questions that still need to be addressed.
November 22, 2018
Video
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the impact of targeted agents in HER2-positive breast cancer.
October 17, 2018
Video
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the status of biosimilars in oncology.
October 16, 2018
Article
One potential approach to improving the response to cancer immunotherapies is to combine such treatments with radiotherapy.
April 29, 2018
Article
Mark Burkard, MD, PhD, discusses an unusual study launched at the University of Wisconsin.
March 09, 2018
Video
Ahmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses cytoreductive surgery in ovarian cancer.
February 22, 2018
Article
UW Carbone Cancer Center will begin treating adults with a “living drug” that employs their own immune cells to fight a common type of aggressive blood cancer.
January 10, 2018
Article
Increasing evidence suggests that immune responses against SCLC cells make immunotherapy a rational approach.
October 11, 2017
Video
Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.
September 16, 2017
Article
According to a new study by UW Carbone Cancer Center researchers, a broadly applicable cancer therapy currently being developed by Cellectar Biosciences may have the potential to work in pediatric solid tumors.
August 16, 2017
Article
PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have broadened in recent months.
May 23, 2017
Article
Mark Burkard, MD, PhD, discusses the steps researchers are taking to address questions on genomics in breast cancer and what subtypes pose the greatest challenges.
May 16, 2017
Video
Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.